Dream Peak Capital Ltd bought a new stake in Synopsys, Inc. (NASDAQ:SNPS - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 297,244 shares of the semiconductor company's stock, valued at approximately $132,592,000. Synopsys accounts for about 13.1% of Dream Peak Capital Ltd's investment portfolio, making the stock its 6th biggest holding. Dream Peak Capital Ltd owned approximately 0.16% of Synopsys as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the company. Sankala Group LLC bought a new stake in Synopsys in the fourth quarter valued at approximately $25,000. Elevation Wealth Partners LLC boosted its stake in shares of Synopsys by 96.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the semiconductor company's stock worth $25,000 after acquiring an additional 27 shares during the period. IMG Wealth Management Inc. bought a new position in shares of Synopsys during the 2nd quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Synopsys during the 4th quarter worth approximately $28,000. Finally, Atlas Capital Advisors Inc. acquired a new position in shares of Synopsys during the 4th quarter worth approximately $32,000. 85.47% of the stock is currently owned by institutional investors and hedge funds.
Synopsys Stock Performance
NASDAQ:SNPS opened at $397.87 on Friday. The stock has a market cap of $76.18 billion, a P/E ratio of 92.10, a PEG ratio of 2.34 and a beta of 1.23. The stock has a 50 day simple moving average of $419.73 and a 200 day simple moving average of $440.22. The company has a current ratio of 1.43, a quick ratio of 1.32 and a debt-to-equity ratio of 0.33. Synopsys, Inc. has a 1-year low of $366.00 and a 1-year high of $615.79.
Synopsys (NASDAQ:SNPS - Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The semiconductor company reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.15 by $0.20. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.25 billion. Synopsys had a return on equity of 5.83% and a net margin of 8.91%.The firm's quarterly revenue was up 41.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 EPS. Synopsys has set its FY 2026 guidance at 14.720-14.800 EPS and its Q3 2026 guidance at 3.630-3.690 EPS. Research analysts anticipate that Synopsys, Inc. will post 10.65 earnings per share for the current year.
Insider Transactions at Synopsys
In other news, CEO Sassine Ghazi sold 14,603 shares of the business's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $458.96, for a total value of $6,702,192.88. Following the completion of the sale, the chief executive officer owned 75,020 shares of the company's stock, valued at approximately $34,431,179.20. The trade was a 16.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Shelagh Glaser sold 3,394 shares of the company's stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $450.02, for a total transaction of $1,527,367.88. Following the completion of the transaction, the chief financial officer owned 14,358 shares in the company, valued at $6,461,387.16. This trade represents a 19.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.56% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. Morgan Stanley cut their price target on Synopsys from $525.00 to $500.00 and set an "equal weight" rating for the company in a report on Wednesday. Needham & Company LLC reiterated a "buy" rating and issued a $580.00 price objective on shares of Synopsys in a report on Thursday, May 28th. Benchmark reissued a "buy" rating on shares of Synopsys in a research report on Wednesday. BNP Paribas Exane raised their target price on shares of Synopsys from $425.00 to $450.00 and gave the stock an "underperform" rating in a research note on Thursday, May 28th. Finally, Berenberg Bank set a $633.00 target price on shares of Synopsys in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Synopsys presently has an average rating of "Moderate Buy" and a consensus price target of $563.59.
Read Our Latest Stock Analysis on Synopsys
Synopsys Profile
(
Free Report)
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Synopsys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Synopsys wasn't on the list.
While Synopsys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.